Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 21841788 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Ungureanu D, et al. (2011) The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 18, 971-6 21841788
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S523-p - JAK2 (human) ▲
Orthologous residues
JAK2 (human): S523‑p, JAK2 (mouse): S523‑p, JAK2 (rat): S523‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  gamma 2a (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE JAK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE JAK2 (human) transfection of wild-type enzyme, phospho-antibody, mutation in upstream enzyme recognition motif, transfection of inactive enzyme JH2 domain phosphorylates JAK2 negative regulatory sites S523 and Y570.
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IFN-gamma no change compared to control

Y570-p - JAK2 (human) ▲
Orthologous residues
JAK2 (human): Y570‑p, JAK2 (mouse): Y570‑p, JAK2 (rat): Y570‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  gamma 2a (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE JAK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE JAK2 (human) transfection of wild-type enzyme, phospho-antibody, mutation in upstream enzyme recognition motif, transfection of inactive enzyme JH2 domain phosphorylates JAK2 negative regulatory sites S523 and Y570.

Y1007-p - JAK2 (human) ▲
Orthologous residues
JAK2 (human): Y1007‑p, JAK2 (mouse): Y1007‑p, JAK2 (rat): Y1007‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  gamma 2a (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IFN-gamma increase wild-type,Y750F, S523A, K581A mutants

Y1008-p - JAK2 (human) ▲
Orthologous residues
JAK2 (human): Y1008‑p, JAK2 (mouse): Y1008‑p, JAK2 (rat): Y1008‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  gamma 2a (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IFN-gamma increase wild-type,Y750F, S523A, K581A mutants


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.